Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Phase 2

Completed

• Conditions: Pandemic H5N1 Influenza
• Interventions: Biological: Adjuvanted H5N1 pandemic influenza vaccine

• Registration Number: NCT01776541
• Lead Sponsor: Novartis Vaccines

Brief Summary

Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01
• Study First Submitted: 2013-01-20
• Study First Submitted QC: 2013-01-23
• Study First Posted: 2013-01-28
• Primary Completion: 2013-06
• Study Completion: 2014-05
• Status Verified: 2015-01
• Results First Submitted: 2015-01-20
• Results First Submitted QC: 2015-01-20
• Last Update Submitted: 2015-01-20
• Results First Posted: 2015-02-03
• Last Update Posted: 2015-02-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 979

Inclusion Criteria

1. Healthy adult subjects 18 to 64 years of age,
2. Individuals willing to provide written informed consent,
3. Individuals in good health,
4. Individuals willing to allow for their serum samples to be stored beyond the study period.

Exclusion Criteria

1. Individuals not able to understand and follow study procedures,
2. History of any significant illness,
3. History of any chronic medical condition or progressive disease,
4. Presence of medically significant cancer,
5. Known or suspected impairment/alteration of immune function,
6. Presence of any progressive or severe neurologic disorder,
7. Presence of any bleeding disorders or conditions that prolongs bleeding time,
8. History of allergy to vaccine components,
9. Receipt of any other investigational product within 30 days prior to entry into the study,
10. History of previous H5N1 vaccination,
11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,
12. Receipt of any other vaccine within 2 weeks prior to entry into the study
13. Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended study vaccination,
14. Pregnant or breast feeding,
15. Females of childbearing potential refusing to use acceptable method of birth control,
16. Body mass index (BMI) ≥ 35 kg/m2,
17. History of drug or alcohol abuse,
18. Any planned surgery during study period,
19. Individuals conducting the study and their immediate family members,
20. Individuals with behavioral or cognitive impairment or psychiatric diseases.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
aH5N1c-High Dose	Adjuvanted H5N1 pandemic influenza vaccine	Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
aH5N1c-Low dose	Adjuvanted H5N1 pandemic influenza vaccine	Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.

Primary Outcome Measures

Name	Time	Method
Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain.	Three weeks after 2nd vaccination (day 43)	The optimal aH5N1c vaccine formulation was evaluated in terms of percentages of subjects achieving HI titers ≥40 against homologous A/H5N1 strain, three weeks after second vaccination with either low dose or high dose of aH5N1c vaccine, according to the Center for Biologics Evaluation and Research (CBER) criterion.; CBER criterion for the adult population is met if the lower limit of the two-sided 95% confidence interval (CI) for the percentages of subjects achieving HI titer ≥40 meets or exceeds 70%.
Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AE), After Any Vaccination.	From day 1 through day 7 after any vaccination.	Safety was assessed using the number of subjects who reported solicited local and systemic AEs following vaccination with either low or high dose of aH5N1c vaccine.
Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.	Three weeks after 2nd vaccination (day 43)	Immunogenicity was measured in terms of the percentages of subjects achieving seroconversion or significant increase in HI titer against the vaccine strain, three weeks after receiving two injections of low dose or high dose of aH5N1c vaccine according to the CBER criterion.; Seroconversion is defined as either a) in subjects with a prevaccination HI titer \<10, a postvaccination titer ≥40; or b) in subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.; CBER criterion for the adult population is met if the lower limit of the two-sided 95% CI for the percentages of subjects achieving seroconversion for HI antibody titer meets or exceeds 40%.
Number of Subjects Reporting Unsolicited AEs After Any Vaccination.	Any unsolicited AEs - day 1 through day 22 after any vaccination. SAEs, NOCDs. medically attended AEs, AESIs, AEs leading to study withdrawal- day 1 to day 387	Safety was assessed using the number of subjects who reported any unsolicited adverse events, adverse events possibly or probably related to study vaccine, serious adverse events (SAEs), new onset of chronic diseases (NOCDs), medically attended AEs, AEs of special interest (AESIs), AEs leading to withdrawal from study following vaccination with either low or high dose of aH5N1c vaccine.

Secondary Outcome Measures

Name	Time	Method
Geometric Mean Ratios Against A/H5N1 Strain Following 2-dose Vaccination Schedule of Either Low Dose or High Dose aH5N1c Vaccine.	Day 1; day 22; day 43 and day 387	Immunogenicity was measured as the geometric mean ratio (GMR). The ratio of postvaccination to prevaccination HI GMTs, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c is reported.; The criterion is met according to the European Committee for Medicinal Products for Human Use (CHMP) criterion if the geometric mean increase GMR (day 43/day 1) in HI antibody titer is \>2.5 for subjects 18-60 years of age.
Percentages Of Subjects With HI Titers ≥40 Against A/H5N1 Strain.	Day 1, day 22, day 43 and day 387	Immunogenicity was assessed in terms of percentage of subjects achieving HI titers ≥40, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose of aH5N1c according to the CHMP criterion.; European Licensure (CHMP) criterion is met if the percentage of subjects achieving (at day 43) HI titers ≥40 is \>70%.
Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain.	Day 22, day 43 and day 387	Immunogenicity was assessed in terms of percentages of subjects achieving seroconversion in HI titers, 3 weeks after first vaccination, 3 weeks after second vaccination and 12 months after second vaccination of either low dose or high dose aH5N1c vaccine according to the CHMP criterion.; Seroconversion is defined as: a) for subjects with a prevaccination HI titer \<10, a postvaccination titer ≥40; or b) for subjects with prevaccination HI titer ≥10, a minimum four-fold rise in postvaccination HI antibody titer.; The criterion is met according to the European (CHMP) guideline if the percentage of subjects achieving seroconversion (at day 43) is \>40%.

Trial Locations

Locations (8)

2 Mercy Health Research; 🇺🇸 St. Louis, Missouri, United States

80 Faculty of Tropical Medicine; 🇹🇭 Bangkok, Thailand

1 Miami Research Associates; 🇺🇸 Miami, Florida, United States

3 Saint Louis University; 🇺🇸 St. Louis, Missouri, United States

4 Benchmark Medical Research; 🇺🇸 Austin, Texas, United States

48 Hunter Clinical Research; 🇦🇺 Newcastle, New South Wales, Australia

46 CMAX; 🇦🇺 Adelaide, South Australia, Australia

47 Linear Clinical Research; 🇦🇺 Nedlands, Western Australia, Australia